Literature DB >> 28427512

Impact of hyperglycemia on the efficacy of chemotherapy-A systematic review of preclinical studies.

Maaike C Gerards1, Daphne L van der Velden2, Joke W Baars2, Dees P M Brandjes3, Joost B L Hoekstra4, Titia M Vriesendorp5, Victor E A Gerdes3.   

Abstract

BACKGROUND: Antineoplastic agents can provoke hyperglycemia in cancer patients with and without diabetes mellitus. We systematically reviewed the impact of hyperglycemia on the efficacy of chemotherapy.
METHODS: MEDLINE was searched for preclinical intervention studies which compared chemotherapy response in hyperglycemic and euglycemic conditions.
RESULTS: Thirteen preclinical studies, including 23 cell lines and 2 animal experiments were identified. In 14 cell lines and 2 animal studies, chemotherapy response was lower in a hyperglycemic (>15mmol/L) compared to a euglycemic environment (5mmol/L). The response was similar in 4 cell lines. In the remaining 5 cell lines, the hyperglycemic environment potentiated chemotherapy efficacy.
CONCLUSION: Hyperglycemia attenuated the antiproliferative effect of chemotherapy in preclinical experiments, but the results are inconsistent. Whether hyperglycemia influences efficacy of chemotherapy in patients needs to be explored.
Copyright © 2017 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chemotherapy; Diabetes mellitus; Hyperglycemia; Therapy response; Tumor microenvironment

Mesh:

Substances:

Year:  2017        PMID: 28427512     DOI: 10.1016/j.critrevonc.2017.03.007

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  8 in total

1.  Characterization of hyperglycemia in patients receiving immune checkpoint inhibitors: Beyond autoimmune insulin-dependent diabetes.

Authors:  Amanda Leiter; Emily Carroll; Danielle Brooks; Jennifer Ben Shimol; Elliot Eisenberg; Juan P Wisnivesky; Matthew D Galsky; Emily J Gallagher
Journal:  Diabetes Res Clin Pract       Date:  2020-12-23       Impact factor: 5.602

2.  The effect of smoking, obesity and diabetes on recurrence-free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy.

Authors:  Alex Croese; Richard Gartrell; Richard Hiscock; Margaret Lee; Peter Gibbs; Ian Faragher; Justin Yeung
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-07

3.  Risk of cause-specific death, its sex and age differences, and life expectancy in post-pancreatitis diabetes mellitus.

Authors:  Jaelim Cho; Stephen J Pandol; Maxim S Petrov
Journal:  Acta Diabetol       Date:  2021-02-15       Impact factor: 4.087

4.  Discovering Associations of Adverse Events with Pharmacotherapy in Patients with Non-Small Cell Lung Cancer Using Modified Apriori Algorithm.

Authors:  Wei Chen; Jun Yang; Hui-Ling Wang; Ya-Fei Shi; Hao Tang; Guo-Hui Li
Journal:  Biomed Res Int       Date:  2018-04-23       Impact factor: 3.411

Review 5.  High glucose: an emerging association between diabetes mellitus and cancer progression.

Authors:  Suangson Supabphol; Wunchana Seubwai; Sopit Wongkham; Charupong Saengboonmee
Journal:  J Mol Med (Berl)       Date:  2021-05-26       Impact factor: 4.599

Review 6.  Hyperglycemia Associated Metabolic and Molecular Alterations in Cancer Risk, Progression, Treatment, and Mortality.

Authors:  Pranay Ramteke; Ankita Deb; Varsha Shepal; Manoj Kumar Bhat
Journal:  Cancers (Basel)       Date:  2019-09-19       Impact factor: 6.639

7.  Metformin suppresses Nrf2-mediated chemoresistance in hepatocellular carcinoma cells by increasing glycolysis.

Authors:  Liangyu Cai; Xin Jin; Jiannan Zhang; Le Li; Jinfeng Zhao
Journal:  Aging (Albany NY)       Date:  2020-09-14       Impact factor: 5.682

Review 8.  Current cancer therapies and their influence on glucose control.

Authors:  Carly Yim; Kerry Mansell; Nassrein Hussein; Terra Arnason
Journal:  World J Diabetes       Date:  2021-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.